Metabolic · In Clinical Trials
Glepaglutide
No lawful US pathway
01 · Overview
Glepaglutide is a long-acting GLP-2 receptor agonist peptide developed for the treatment of short bowel syndrome (SBS), designed as a ready-to-use injection (PMID 39851172). GLP-2 promotes intestinal growth and enhances nutrient and fluid absorption, which can improve intestinal function in patients with reduced bowel length.
It is given by subcutaneous injection once or twice weekly in clinical trials (PMID 39708985).
02 · Research summary & key findings
In the 24-week phase 3 EASE SBS-1 trial in 106 patients with SBS and intestinal failure, twice-weekly glepaglutide reduced weekly parenteral support volume more than placebo (-5.13 vs. -2.85 L/week), while once-weekly dosing did not differ significantly from placebo (Gastroenterology, 2025) (PMID 39708985). Twice-weekly treatment also increased the proportion of patients with clinical response and with at least one fewer day per week of parenteral support, and was reported as safe and well tolerated (PMID 39708985). Five patients (14 percent) on twice-weekly glepaglutide were completely weaned from parenteral support, versus none on placebo (PMID 39708985).
03 · Regulatory status
Glepaglutide is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
No lawful pathway today
Glepaglutide is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 13 FDA-approved compounds in Metabolic
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for metabolic health and weight?
Glepaglutide is still in clinical trials, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on metabolic health and weight, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
References
- [1]Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled Trial Gastroenterology, 2025. PMID 39708985
- [2]Creating Glepaglutide, the First Long-Acting GLP-2 Analogue to Enable a Ready-to-Use Injection J Med Chem, 2025. PMID 39851172
Primary literature
- PubMed: "Glepaglutide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Glepaglutide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Glepaglutide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Metabolic
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.